BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

869 related articles for article (PubMed ID: 17034579)

  • 1. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
    Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA
    Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
    Massanella M; Tural C; Papagno L; Garcia E; Jou A; Bofill M; Autran B; Clotet B; Blanco J
    Antivir Ther; 2010; 15(3):333-42. PubMed ID: 20516553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin.
    Neau D; Galpérine T; Legrand E; Pitard V; Neau-Cransac M; Moreau JF; Ragnaud JM; Dupon M; Fleury H; Lafon ME
    HIV Med; 2003 Apr; 4(2):120-6. PubMed ID: 12702132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment.
    Soldevila B; Alonso N; Martínez-Arconada MJ; Morillas RM; Planas R; Sanmartí AM; Martínez-Cáceres EM
    J Viral Hepat; 2011 Jun; 18(6):384-92. PubMed ID: 20487258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.
    Capa L; Soriano V; García-Samaniego J; Nuñez M; Romero M; de Mendoza C; Cascajero A; Muñoz F; González-Lahoz J; Benito JM
    Antivir Ther; 2007; 12(4):459-68. PubMed ID: 17668554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children.
    Resino S; Galán I; Bellón JM; Navarro ML; León JA; Muñoz-Fernandez MA
    J Clin Immunol; 2003 Jul; 23(4):279-89. PubMed ID: 12959220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of naïve (CD45RA+) and memory (CD45RO+) T-cells in HIV-infected Puerto Rican population.
    Roman M; Rodriguez JW; Pagán NO; Rios-Olivares E; Amill A; Hunter R
    P R Health Sci J; 2002 Sep; 21(3):195-201. PubMed ID: 12243109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dynamic changes in programmed death-1 expression on the surface of T cells in chronic hepatitis C patients undergoing interferon therapy].
    Dong RQ; Zhou DF; Han R; Zhou JY; Zhao CY; Zhen Z
    Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):899-902. PubMed ID: 24636290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection.
    Sreenarasimhaiah J; Jaramillo A; Crippin J; Lisker-Melman M; Chapman WC; Mohanakumar T
    Hum Immunol; 2003 May; 64(5):497-504. PubMed ID: 12691700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?
    Lee S; Hammond T; Watson MW; Flexman JP; Cheng W; Fernandez S; Price P
    Clin Exp Immunol; 2010 Jul; 161(1):118-26. PubMed ID: 20408862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy.
    Resino S; Galán I; Pérez A; León JA; Seoane E; Gurbindo D; Muñoz-Fernandez MA
    Clin Exp Immunol; 2004 Sep; 137(3):570-7. PubMed ID: 15320908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of pegylated interferon alpha and ribavirin therapy of chronic hepatitis C on peripheral blood and intrahepatic lymphocytes].
    Tomasiewicz K; Modrzewska R; Korobowicz E
    Pol Merkur Lekarski; 2009 Jan; 26(151):19-23. PubMed ID: 19391501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon.
    Arizcorreta A; Brun F; Fernández-Gutiérrez C; García Juárez R; Guerrero F; Pérez-Guzmán E; Girón-González JA
    Clin Microbiol Infect; 2004 Dec; 10(12):1067-74. PubMed ID: 15606633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
    Marchetti G; Nasta P; Bai F; Gatti F; Bellistrì GM; Tincati C; Borghi F; Carosi G; Puoti M; Monforte Ad
    PLoS One; 2012; 7(2):e32028. PubMed ID: 22363790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children.
    Resino S; Galán I; Pérez A; Ramos JT; Bellón JM; Fontelos PM; de José MI; Gutiérrez MD; Cabrero E; Muñoz-Fernández MA
    AIDS Res Hum Retroviruses; 2005 May; 21(5):398-406. PubMed ID: 15929702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy.
    de Mendoza C; Martin-Carbonero L; Barreiro P; de Baar M; Zahonero N; Rodriguez-Novoa S; Benito JM; González-Lahoz J; Soriano V
    AIDS; 2007 Mar; 21(5):583-8. PubMed ID: 17314520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfected patients.
    Reiberger T; Payer BA; Kosi L; Heil PM; Rieger A; Peck-Radosavljevic M;
    J Infect Dis; 2011 Jun; 203(12):1802-6. PubMed ID: 21606538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.